A RABIES-SPECIFIC HUMAN MONOCLONAL-ANTIBODY THAT PROTECTS MICE AGAINST LETHAL RABIES

被引：24

作者：

ENSSLE, K ^{[1
]}

KURRLE, R ^{[1
]}

KOHLER, R ^{[1
]}

MULLER, H ^{[1
]}

KANZY, EJ ^{[1
]}

HILFENHAUS, J ^{[1
]}

SEILER, FR ^{[1
]}

机构：

[1] BEHRINGWERKE AG, SERV, W-3550 MARBURG, GERMANY

来源：

HYBRIDOMA | 1991年 / 10卷 / 05期

关键词：

D O I：

10.1089/hyb.1991.10.547

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

According to a recommendation from WHO (World Health Organisation) for prevention of a possible rabies infection, active vaccination has to be combined with application of immunoglobulin to get a fast protective effect. At present, preparations of purified human or equine rabies-specific immunoglobulin are used. We have generated a human rabies-specific monoclonal antibody (huMAb) by immortalization of human B-cells with Epstein Barr Virus (EBV), followed by fusion with a mouse myeloma cell. The resulting clone TW-1 secrets an IgGl-lambda-huMAb which specifically reacts in ELISA with 5 laboratory rabies virus strains of serotype 1 and DUV3 (Duvenhage, serotype 4). Western Blot analysis revealed fine specificity for the G glycoprotein (gp67) of rabies virus. HuMAb TW-1 neutralizes rabies virus in vitro (RFFIT) as well as in vivo and protects rabies infected mice. Compared to polyclonal human rabies immunoglobulins, huMAb TW-1 is advantageous, because of its defined specificity and the very low amounts of total protein needed for therapeutic effects.

引用

页码：547 / 556

页数：10

共 28 条

[1]

ARKO RJ, 1973, ANTIBODY BINDING TES, P292

[2]

Atanasiu P, 1973, Monogr Ser World Health Organ, P314

[3]

BAER GM, 1988, REV INFECT DIS, V10, pS739

[4] PURIFIED CHICK-EMBRYO-CELL (PCEC) RABIES VACCINE - ITS POTENCY PERFORMANCE IN DIFFERENT TEST SYSTEMS AND IN HUMANS [J].